IL-8 level as a determinant of responsivity of a cancer to treatment

1. A method for determining if a subject with a malignant tumor or blood cancer has a malignant tumor or blood cancer that is responsive to an agent selected from the group consisting of:

comprising determining an IL-8 level in the blood or serum of the subject, administering the agent to the subject, and then determining an IL-8 level in the blood or serum of the subject again;

wherein said condition is determined to be unresponsive to the agent if the IL-8 level does not decrease after the administration relative to before the administration; and

wherein the condition is determined to be responsive to the agent if IL-8 level does decrease after the administration relative to before the administration.

2. The method of claim 1 wherein the subject is human and the agent is represented by a structural formula selected from the group consisting of:

3. A method for determining if a subject with a malignant tumor or blood cancer has a malignant tumor or blood cancer that is responsive to an agent selected from the group consisting of:

wherein the tumor or blood cancer is a member selected from the group consisting of: lung cancer, lung adenocarcinoma, non small cell lung cancer, pancreatic cancer, pancreatic carcinoma, exocrine pancreatic carcinoma, colon cancer, colorectal carcinoma, colon adenocarcinoma, myeloid leukemia, acute myelogenous leukemia, chronic myelogenous leukemia, chronic myelomonocytic leukemia, thyroid cancer, bladder carcinoma, epidermal carcinoma, melanoma, breast cancer, prostate cancer, head and neck cancer, squamous cell cancer of the head and neck, ovarian cancer, brain cancer, glioma, glioma blastoma multiforme, cancer of mesenchymal origin, fibrosarcoma, rhabdomyosarcoma, sarcoma, teratocarcinoma, neuroblastoma, kidney carcinoma, hepatoma, non-Hodgkin's lymphoma, multiple myeloma, and anaplastic thyroid carcinoma;

comprising determining an IL-8 level in the blood or serum of the subject, administering the agent to the subject, and then determining an IL-8 level in the blood or serum of the subject again;

wherein said condition is determined to be unresponsive to the agent if the IL-8 level does not decrease after the administration relative to before the administration; and

wherein the condition is determined to be responsive to the agent if the IL-8 level does decrease after the administration relative to before the administration.

4. The method of claim 3 wherein the subject is human and the malignant tumor is melanoma.

5. The method of claim 3 wherein the agent is represented by the structural formula:

6. The method of claim 3 wherein the agent is represented by the structural formula:

7. The method of claim 3 wherein the agent is represented by the structural formula:

8. The method of claim 3 wherein the agent is represented by the structural formula:

9. The method of claim 3 wherein the agent is represented by the structural formula:

10. The method of claim 3 wherein the agent is represented by the structural formula:

11. The method of claim 3 wherein the agent is represented by the structural formula:

12. The method of claim 3 wherein the agent is represented by the structural formula:

13. The method of claim 3 wherein the agent is represented by the structural formula:

14. The method of claim 3 wherein the agent is represented by the structural formula:

15. The method of claim 3 wherein the agent is represented by the structural formula:

16. The method of claim 3 wherein the agent is represented by the structural formula:

17. The method of claim 3 wherein the agent is represented by the structural formula:

18. The method of claim 3 wherein the agent is represented by the structural formula:

19. The method of claim 3 wherein the agent is represented by the structural formula:

20. The method of claim 3 wherein the agent is represented by the structural formula:

21. The method of claim 3 wherein the agent is represented by the structural formula: